Cambodia Pharmaceuticals and Healthcare Report Q4 2012
Business Monitor International, October 2012, Pages: 57
The Cambodia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Cambodia's pharmaceuticals and healthcare industry.
BMI View: Lacklustre efforts by the government to boost healthcare means that the Cambodia will be the least attractive to pharmaceutical investors as compared to its South East Asian peers as the population are unable to afford new treatments. Over the longer term we expect such trends to change and active participation in the Association of Southeast Asia Nations (ASEAN) Economic Community will boost its attractiveness.
Headline Expenditure Projections:
- Pharmaceuticals: KHR718bn (US$178mn) in 2011 to KHR806bn (US$193mn) in 2012;
+12.2% in local currency terms and +8.8% in US dollar terms. Growth forecast unchanged from Q312, although we have adjusted the absolute value following reassessment of the market size.
- Healthcare: KHR2,982bn (US$737mn) in 2011 to KHR3,312bn (US$794mn) in 2012; +11.1%
in local currency terms and +7.8% in US dollar terms. Forecast unchanged from Q312.
- Medical Devices: KHR108bn (US$27mn) in 2011 to KHR118bn (US$28mn) in 2011; +9.8% in local currency terms and +6.6% in US dollar terms. Forecast unchanged from Q312.
Risk/Reward Rating:
Cambodia remains last out of the18 key markets in BMI’s Q412 Asia Pacific Pharmaceutical Risk/Reward Ratings with a score of 33.5, significantly lower than the regional average of 53.3. Near-term risks includes rampant corruption and poor healthcare provision although its membership in the ASEAN can boost its long-term attractiveness.
Key Trends And Developments:
- In August 2012, a Chinese medical delegation comprising seven traditional Chinese medical doctors will offer five free clinic services in two cities of Cambodia - Phnom Penh and Siem Reap. The free clinic services aim to help local patients through Chinese traditional treatments,
said Zhou Xiaobao, the delegation head.
- In July 2012, DKSH Healthcare and GlaxoSmithKline (GSK) have signed an agreement under which DKSH Healthcare will distribute GSK's pharmaceutical and vaccine products in Cambodia.
BMI Economic View:
Cambodia's high dollarisation rate, estimated to be 80%, should gradually fall over the coming years as market-friendly economic policies inspire more confidence in the domestic currency. This, in turn, should leave the economy less exposed to external shocks.
BMI Political View:
Cambodia's long-term political outlook largely depends on the ruling Cambodian People's Party (CPP)'s ability to address widespread corruption and income inequality, which have been fuelling public dissent against the government in recent years. Meanwhile, the lack of effective opposition to challenge the CPP at elections suggests that the party will continue to dominate the political scene over the coming years.
Executive Summary 5
SWOT Analysis 7
Cambodia Pharmaceuticals And Healthcare Industry SWOT 7
Pharmaceutical Risk/Reward Ratings 8
Table: Asia Pacific Pharmaceutical Risk/Reward Ratings, Q412 8
Rewards 9
Risks 9
Market Summary 11
Regulatory Regime 12
Intellectual Property Environment 12
Counterfeit Medicines 13
Pricing And Reimbursement 15
Industry Trends And Developments 17
Epidemiology 17
Healthcare Sector 19
Health Insurance 20
Research & Development Sector 21
Clinical Trials 21
Medical Devices 21
Industry Forecast Scenario 23
Overall Market Forecast 23
Table: Pharmaceutical Sales Indicators 2008-2016 24
Key Growth Factors – Industry 25
Table: Healthcare Expenditure Indicators 2008-2016 26
Table: Healthcare Governmental Indicators 2008-2016 26
Table: Healthcare Private Indicators 2008-2016 27
Key Growth Drivers – Macroeconomic 28
Table: Cambodia - Economic Activity, 2011-2016 29
Medical Device Market Forecast 30
Table: Medical Devices Sales Indicators 2008-2016 31
Pharmaceutical Trade Forecast 32
Table: Exports and Imports Indicators 2008-2016 34
Key Risks To our Forecast Scenario 35
Competitive Landscape 36
Pharmaceutical Industry 36
Pharmaceutical Company Developments 38
Pharmaceutical Wholesale 38
Pharmaceutical Retail 39
Company Profiles 41
Local Companies 41
Cambodia Pharmaceuticals & Healthcare Report Q4 2012
© Business Monitor International Ltd
Page 4
PharmaProduct Manufacturing (PPM) 41
Cambodia Pharmaceutical Enterprise 43
Multinational Companies 44
Sanofi 44
Pfizer 46
Demographic Outlook 47
Table: Cambodia's Population By Age Group, 1990-2020 ('000) 48
Table: Cambodia's Population By Age Group, 1990-2020 (% of total) 48
Table: Cambodia's Key Population Ratios, 1990-2020 49
Table: Cambodia's Rural And Urban Population, 1990-2020 50
Glossary 51
BMI Methodology 53
How We Generate Our Pharmaceutical Industry Forecasts 53
Pharmaceuticals Risk/Reward Ratings Methodology 54
Ratings Overview 54
Table: Pharmaceutical Business Environment Indicators 55
Weighting 56
Table: Weighting Of Components 56
Sources 56
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
